Navigation Links
Biogen Idec and Isis Pharmaceuticals Announce Collaboration For Antisense Programs To Treat Neurological Disorders
Date:12/10/2012

, Isis will receive double-digit royalties on sales of drugs. Isis will be responsible for development of the drugs through the completion of the initial Phase 2 clinical trial, with Biogen Idec providing advice and assistance on research and the clinical trial design and conduct and regulatory strategy for each program. If Biogen Idec exercises its option, it will assume global development, regulatory and commercialization responsibilities. 

"We look forward to broadening our drug discovery and development efforts to include new neurological disease targets with Biogen Idec, a world leader in neurological diseases. Combining our antisense drug discovery with Biogen Idec's expertise in severe neurological diseases has significantly enhanced the development of our spinal muscular atrophy and myotonic dystrophy programs. For example, Biogen Idec's contributions have added significant value across multiple areas, such as government affairs, biomarker development, clinical trial design and regulatory expertise, bolstering our development activities for these programs," said B. Lynne Parshall, chief operating officer and chief financial officer at Isis. "We have been very successful in our partnering efforts this year, driven primarily by the advancement of the drugs in our pipeline. The high level of interest in our drug discovery technologies allows us to select the optimal partner for each program, while commanding significant value for our assets."

This collaboration follows two worldwide option and collaboration agreements between Biogen Idec and Isis, which were announced earlier in 2012, to develop and commercialize antisense drugs for the treatment of spinal muscular atrophy and myotonic dystrophy type 1. 

About Biogen Idec
Through cutting-edge science and medicine, Biogen Idec discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Biogen Idec and Regulus Therapeutics Form Collaboration to Explore microRNA Biomarkers for Disease Monitoring and Response to Therapy
2. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
3. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
4. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
5. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
6. Icahn Issues Statement Regarding Amylin Pharmaceuticals
7. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
8. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
9. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
10. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
11. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... WESTPORT, Conn. , Sept. 16, 2014 /PRNewswire/ ... wholly owned subsidiary of TriStar Wellness Solutions(R), ... and marketer of advanced medical products, announced today ... platform has grown by 39 percent, and microdispersed ... year-to-date though August 2014.  Overall, TWSI expects third ...
(Date:9/16/2014)... 2014   Vestagen Technical Textiles, Inc. today ... hospitals. The myComfort™ line of patient apparel is protected ... is fluid repellant, breathable and in studies done in ... bacteria on the fabric i . "It,s ... chain of transmission. We want myComfort to be a ...
(Date:9/16/2014)... 2014 The Lupus Foundation of America and ... today released results from UNVEIL: understanding the impact of ... lupus journey and the challenges not only for those ... UNVEIL study, which involved over 1,000 people with lupus ... on all aspects of life including family, work, finances, ...
Breaking Medicine Technology:HemCon Medical Technologies, Inc. Projects Strong Third Quarter Revenues 2HemCon Medical Technologies, Inc. Projects Strong Third Quarter Revenues 3HemCon Medical Technologies, Inc. Projects Strong Third Quarter Revenues 4New Vestagen Patient Garments Aim to Minimize Pathogen Transmission Inside Hospitals 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 3"UNVEIL" Survey Reveals a Life Interrupted by Lupus 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 5
(Date:9/16/2014)... use among teens in the United States is on the ... the new study also found that alcohol use, binge drinking ... the ages of 12 and 17 also dropped between 2002 ... 12 and older across the United States revealed that between ... age group also dropped from 8.9 percent to 5.2 percent. ...
(Date:9/16/2014)... equally preserved in cancer patients suffering from malignant spinal ... 10 Gy of radiation therapy (RT), compared to patients ... RT each, according to research presented today at the ... , Malignant spinal cord compression (MSCC) is a ... occurs when a tumor,s secondary deposit presses on the ...
(Date:9/16/2014)... to be on the heavy side. Researchers at the ... seven in every ten obese adults underestimate how much ... much less often. Mothers of overweight or obese children ... misjudge their obese mothers, size, says lead author Tracy ... in the Journal of General Internal Medicine , ...
(Date:9/16/2014)... -- While abnormalities in the adrenergic and noradrenergic ... thought to play a role in the development ... has been no genetic evidence of this connection. ... Columbia University,s Mailman School of Public Health and ... the ADRB2 gene and childhood adversity. For individuals ...
(Date:9/16/2014)... The Pain Center of Arizona (TPC), ... has selected Analance ™, Ducen ’s BI ... TPC seeing hundreds of thousands of patients annually, the ... through “home grown” systems trying to piece together actionable ... “Our current tools were not scalable and, in ...
Breaking Medicine News(10 mins):Health News:Fewer U.S. Teens Using Illegal Drugs and Alcohol, Report Finds 2Health News:Cancer patients with malignant spinal cord compression have preserved mobility 2Health News:Cancer patients with malignant spinal cord compression have preserved mobility 3Health News:Cancer patients with malignant spinal cord compression have preserved mobility 4Health News:Poor body size judgement can lead to increased tolerance of obesity 2Health News:Evidence of genetic link to PTSD in soldiers exposed to childhood trauma 2Health News:Evidence of genetic link to PTSD in soldiers exposed to childhood trauma 3Health News:The Pain Center of Arizona (TPC) Implements Analance™ BI for Actionable Intelligence 2Health News:The Pain Center of Arizona (TPC) Implements Analance™ BI for Actionable Intelligence 3
... leading neuromodulation company, announced today that beginning January ... by Medicare for incomplete spinal cord injury patients ... Centers for Medicare and Medicaid Services (CMS) establishes ... stimulation (FES) devices including the NESS L300™ Foot ...
... changed in a heartbeat for successful freelance writer Lee Woodruff ... Tonight, was wounded while broadcasting from Iraq. Her experience as ... be the focus of her keynote address at URAC,s Best ... Exhibit, April 1-2, 2009 in Orlando, Fla. , ...
... 11 Rosalind Franklin University,of Medicine and Science ... the first in the nation to provide its students with ... The new,system enables medical educators to present students with individual ... has a proven,accuracy rate of over 90 percent. , ...
... Pain Therapeutics, Inc. (Nasdaq: PTIE ) has received a ... for its New Drug Application (NDA) for REMOXY(R), an abuse-resistant controlled-release ... determined that the NDA is not approved in its present form. ... believes additional non-clinical data will be required to support the approval ...
... 11 Preferred Management Corporation of,Shawnee, OK ... two hospitals near Amarillo, Texas. The hospitals, ... General Hospital in Wellington, are both,federally designated ... are administered by Preferred Management Corporation which ...
... to be ignoring message that methamphetamine is dangerous , , ... that utilizes graphic images actually may not be very ... Project (MMP), created in 2005, featured images that showed ... perceived success of the program had resulted in its ...
Cached Medicine News:Health News: Medicare to Reimburse for the Bioness L300™ Foot Drop System for Spinal Cord Injury 2Health News: Medicare to Reimburse for the Bioness L300™ Foot Drop System for Spinal Cord Injury 3Health News:Best-selling Author Lee Woodruff, Futurist Ian Morrison to Speak at URAC's Best Practices Conference 2Health News:Best-selling Author Lee Woodruff, Futurist Ian Morrison to Speak at URAC's Best Practices Conference 3Health News:Rosalind Franklin University of Medicine and Science First in Illinois to Equip Students With Computerized Diagnosis System 2Health News:Pain Therapeutics Receives Complete Response Letter From FDA for REMOXY(R) 2Health News:Pain Therapeutics Receives Complete Response Letter From FDA for REMOXY(R) 3Health News:Preferred Management Corp. Installs OpusClinicalSuite(R) at 2 Texas Hospitals 2Health News:Preferred Management Corp. Installs OpusClinicalSuite(R) at 2 Texas Hospitals 3Health News:Study Questions Value of Anti-Meth Campaign 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: